CompletedPhase 4

Ameliorating Contrast Induced Nephropathy After Coronary Angiography

Egypt120 participantsStarted 2023-12-01

Plain-language summary

Given the limited understanding of the impact of statin and N-acetyl cysteine use before angiography in preventing contrast-induced nephropathy (CIN), the objective of this study is to evaluate the effectiveness of atorvastatin in preventing CIN among patients undergoing coronary angiography.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Undergoing elective Coronary angiography who will receive coronary angiography contrast media. * Must have at least two consecutive serum creatinine measurements (Before and after Contrast exposure) Exclusion Criteria: * Pregnant or lactating women * Patients with Serum creatinine conc of \>2.1 mg/Dl * Patients undergoing emergency primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. * Prior exposure to contrast media within 7 days * Contraindication for a high-dose statin, N-acetyl Cysteine prescription

What they're measuring

Contrast induced nephropathy (CIN) incidence

Timeframe: 24-48 hours after PCI

Trial details

NCT IDNCT06139952

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03-01

View on ClinicalTrials.gov More Coronary Artery Disease trials